Meabco A/S expands combination trials with more existing anti-cancer drugs

The European Patent Office (EPO) informs that it has decided to grant a European Patent (Anti-Cancer) for the BP-C1 drug.

MEABCO’S BP-Cx-1 widens the number of first line cytostatic agents

Continuation into phase IIB trials.